Co-infections in people with COVID-19: a systematic review and meta-analysis - 25/07/20
, Benjamin Lim b , Vadsala Baskaran a, c , Wei Shen Lim c
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | SARS-CoV-2, the cause of COVID19 disease, has spread globally since late 2019 |
• | Bacterial coinfections associated with mortality in previous influenza pandemics |
• | Proportion of COVID19 patients with bacterial coinfection less than in flu pandemics |
• | Higher proportion of critically-ill with bacterial coinfections than in mixed setting |
• | Bacterial co-pathogen profiles different to those in influenza co-infections |
• | Fungal coinfection diagnosis difficult so high level suspicion in critically-ill |
Abstract |
Objectives |
In previous influenza pandemics, bacterial co-infections have been a major cause of mortality. We aimed to evaluate the burden of co-infections in patients with COVID-19.
Methods |
We systematically searched Embase, Medline, Cochrane Library, LILACS and CINAHL for eligible studies published from 1 January 2020 to 17 April 2020. We included patients of all ages, in all settings. The main outcome was the proportion of patients with a bacterial, fungal or viral co-infection. .
Results |
Thirty studies including 3834 patients were included. Overall, 7% of hospitalised COVID-19 patients had a bacterial co-infection (95% CI 3-12%, n=2183, I2=92·2%). A higher proportion of ICU patients had bacterial co-infections than patients in mixed ward/ICU settings (14%, 95% CI 5-26, I2=74·7% versus 4%, 95% CI 1-9, I2= 91·7%). The commonest bacteria were Mycoplasma pneumonia, Pseudomonas aeruginosa and Haemophilus influenzae. The pooled proportion with a viral co-infection was 3% (95% CI 1-6, n=1014, I2=62·3%), with Respiratory Syncytial Virus and influenza A the commonest. Three studies reported fungal co-infections.
Conclusions |
A low proportion of COVID-19 patients have a bacterial co-infection; less than in previous influenza pandemics. These findings do not support the routine use of antibiotics in the management of confirmed COVID-19 infection.
Le texte complet de cet article est disponible en PDF.Keywords : Coronavirus, COVID-19, Coinfection, Meta-Analysis
Plan
Vol 81 - N° 2
P. 266-275 - août 2020 Retour au numéro
Article précédent
- Modelling SARS-COV2 Spread in London: Approaches to Lift the Lockdown
- Lara Goscé, Professor Andrew Phillips, Paula Spinola, Dr Rishi K. Gupta, Professor Ibrahim Abubakar
- Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
- Carlos J. Pirola, Silvia Sookoian
Bienvenue sur EM-consulte, la référence des professionnels de santé.